VERA Stock Summary and Trading Ideas (Vera Therapeutics - Class A | NASDAQ:VERA)

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Vera Therapeutics - Class A trades on the NASDAQ stock market under the symbol VERA.

As of September 9, 2026, VERA stock price declined to $33.78 with 884,117 million shares trading.

VERA has a beta of 0.85, meaning it tends to be less sensitive to market movements. VERA has a correlation of 0.03 to the broad based SPY ETF.

VERA has a market cap of $2.42 billion. This is considered a Mid Cap stock.

In the last 3 years, VERA traded as high as $56.05 and as low as $9.24.

The top ETF exchange traded funds that VERA belongs to (by Net Assets): XBI, VTI, VXF, VTWO, SCHA.

VERA has outperformed the market in the last year with a return of +34.7%, while the SPY ETF gained +18.4%. In the last 3 month period, VERA beat the market returning +6.2%, while SPY returned +3.7%. However, in the most recent 2 weeks VERA has underperformed the stock market by returning -8.3%, while SPY returned -0.5%.

VERA support price is $34.01 and resistance is $36.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERA shares will trade within this expected range on the day.